B-cell activation, differentiation, and contraction

Last updated: December 22, 2025

B-cell activation, differentiation, and contraction

NMBE hematoinmuno

NMBE hematoinmuno

Blood histology
Blood components
Erythropoietin
Blood groups and transfusions
Platelet plug formation (primary hemostasis)
Coagulation (secondary hemostasis)
Role of Vitamin K in coagulation
Clot retraction and fibrinolysis
Iron deficiency anemia
Beta-thalassemia
Alpha-thalassemia
Sideroblastic anemia
Anemia of chronic disease
Lead poisoning
Hemolytic disease of the newborn
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Autoimmune hemolytic anemia
Pyruvate kinase deficiency
Paroxysmal nocturnal hemoglobinuria
Sickle cell disease (NORD)
Hereditary spherocytosis
Aplastic anemia
Fanconi anemia
Megaloblastic anemia
Folate (Vitamin B9) deficiency
Vitamin B12 deficiency
Diamond-Blackfan anemia
Acute intermittent porphyria
Porphyria cutanea tarda
Hemophilia
Vitamin K deficiency
Bernard-Soulier syndrome
Glanzmann's thrombasthenia
Hemolytic-uremic syndrome
Immune thrombocytopenia
Thrombotic thrombocytopenic purpura
Von Willebrand disease
Disseminated intravascular coagulation
Heparin-induced thrombocytopenia
Antithrombin III deficiency
Factor V Leiden
Protein C deficiency
Protein S deficiency
Antiphospholipid syndrome
Hodgkin lymphoma
Non-Hodgkin lymphoma
Chronic leukemia
Acute leukemia
Myelodysplastic syndromes
Polycythemia vera (NORD)
Myelofibrosis (NORD)
Essential thrombocythemia (NORD)
Langerhans cell histiocytosis
Multiple myeloma
Microcytic anemia: Pathology review
Non-hemolytic normocytic anemia: Pathology review
Intrinsic hemolytic normocytic anemia: Pathology review
Extrinsic hemolytic normocytic anemia: Pathology review
Macrocytic anemia: Pathology review
Heme synthesis disorders: Pathology review
Coagulation disorders: Pathology review
Platelet disorders: Pathology review
Mixed platelet and coagulation disorders: Pathology review
Thrombosis syndromes (hypercoagulability): Pathology review
Lymphomas: Pathology review
Leukemias: Pathology review
Plasma cell disorders: Pathology review
Myeloproliferative disorders: Pathology review
Anticoagulants: Heparin
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Ribonucleotide reductase inhibitors
Topoisomerase inhibitors
Platinum containing medications
Anti-tumor antibiotics
Microtubule inhibitors
DNA alkylating medications
Monoclonal antibodies
Antimetabolites for cancer treatment
Thymus histology
Spleen histology
Lymph node histology
Cytokines
Innate immune system
Complement system
T-cell development
B-cell development
MHC class I and MHC class II molecules
T-cell activation
B-cell activation, differentiation, and contraction
Antibody classes
Type I hypersensitivity
Type II hypersensitivity
Type III hypersensitivity
Type IV hypersensitivity
Graft-versus-host disease
X-linked agammaglobulinemia
Selective immunoglobulin A deficiency
Common variable immunodeficiency
IgG subclass deficiency
Hyperimmunoglobulin E syndrome
Thymic aplasia
DiGeorge syndrome
Severe combined immunodeficiency
Adenosine deaminase deficiency
Ataxia-telangiectasia
Hyper IgM syndrome
Wiskott-Aldrich syndrome
Leukocyte adhesion deficiency
Chediak-Higashi syndrome
Chronic granulomatous disease
Complement deficiency
Hereditary angioedema
Asplenia
Mycobacterium tuberculosis (Tuberculosis)
Anemia: Clinical
ELISA (Enzyme-linked immunosorbent assay)
HIV and AIDS: Pathology review
HIV (AIDS)
Atopic dermatitis
Papulosquamous and inflammatory skin disorders: Pathology review
Bullous pemphigoid
Pemphigus vulgaris
Stevens-Johnson syndrome
Erythema multiforme
Antiplatelet medications
Immunodeficiencies: T-cell and B-cell disorders: Pathology review
Immunodeficiencies: Combined T-cell and B-cell disorders: Pathology review
Immunodeficiencies: Phagocyte and complement dysfunction: Pathology review

Transcript

Watch video only

The adaptive immune response is highly specific for each invader. The cells of the adaptive immune response have receptors that differentiate one pathogen from another by their unique parts - called antigens. The key cells of the adaptive immune response are the lymphocytes - the B and T cells. B cells develop in the bone marrow where they undergo a process called VDJ rearrangement to generate a massively diverse set of B cell receptors.

The B cell receptor is essentially an antibody except that it has a transmembrane part that goes through the membrane attaching the receptor to the surface of the B cell. The B cell receptor has two heavy chains and two light chains, and the region or fragment of the B cell receptor that binds the antigen is called the fragment-antigen binding or Fab region.

The Fab region is where the ends of the heavy and light chains meet, and there are two Fab fragments on each B cell receptor. The remainder of the heavy chain makes up the fragment-crystalline region, also called Fc, which crystallizes in solution and is also constant or identical in every antibody of a particular type.

The two heavy chains are linked to one another by disulfide bonds, and each heavy chain is also linked to a light chain by a disulfide bond. Each B cell receptor has two identical heavy and light chains, resulting in two identical antigen binding sites. As the B cell develops into a plasma cell, the B cell receptor gets secreted as an antibody with the exact same antigen specificity. However, the heavy chain actually changes as the B cell develops.

There are 5 major types of heavy chains which encode the isotypes or classes of immunoglobulins: IgM, IgD, IgG, IgA, and IgE. These five are encoded by heavy chain genes which are referred to by the Greek letters mu, delta, gamma, alpha, and epsilon.

When a B cell is first developing it initially expresses the mu heavy chain, and as a result all of the B cell receptors are IgMs that are on the cell surface.

When the B cell finishes developing, it undergoes a process called alternative splicing. Alternative splicing is a process by which the cell expresses the heavy chain exons for both mu and delta allowing for both IgM and IgD to be simultaneously expressed on the surface.

At this point the B cell is mature but still naive. Having IgD on the B cell surface is a like a young adult with a driver’s license; they’re able to go out and explore the world – in the B cell’s case, that means all of the body’s lymphatic system - but the cells haven’t been exposed to much and don’t know how they’ll react to foreign antigens.

Once the B cells start to explore the body’s lymphatic system they travel from lymph node to lymph node in search of antigens.

Lymph nodes are scattered throughout your body, and each one is a highly organized structure where millions of B cells, T cells, antigens, and antigen presenting cells pass through every day - like a busy airport.

When B cells and T cells get into the lymph nodes, they first enter the paracortical region. The T cells remain there, while the B cells migrate to the neighboring cortical region of the lymph node, where they form the primary lymphoid follicles. If a B cell gets activated, it starts replicating within a follicle, and it forms a germinal center. And a follicle with a germinal center is called a secondary lymphoid follicle. Various antigens enter the lymph node through the afferent lymphatic vessel, and they percolate through the paracortex and through to the follicle. It looks a bit like a game of plinko where the antigens get to interact with lots of B cells in the follicle. B cells, unlike T cells, can recognize a wide variety of antigens including peptides, carbohydrates, and lipids in their native form, meaning that they don’t require antigen presenting cells to process or present the antigen.

In order for the B cell to be activated, the antigen first needs to bind to and induce the crosslinking of the B cell receptors. When two B cell receptors get crosslinked, their intracellular chains, the side chains - Ig alpha and Ig beta, and CD19 all cluster together. Each of these side chains have something called an immune receptor tyrosine-based activation motif, or ITAM for short. The ITAM is a conserved sequence of amino acids that includes two tyrosine amino acids. Binding of the antigen to the B-cell receptor signals the phosphorylation of these tyrosine molecules, which then triggers a chain of events within the cell that ends with the activation of the major transcription factors - NFkappaB and NFAT. These transcription factors increase the expression of certain cytokines and anti-apoptotic cell surface markers like Bcl-2, which are required for the proliferation and differentiation of B cells.

Key Takeaways

B cells are activated when they encounter an antigen that they recognize. The antigen binds to the B cell's surface receptors, which activates and triggers it to divide and differentiate into an antibody-secreting plasma cell. Plasma cells produce antibodies that bind to the antigen and neutralize it.

The differentiation process is controlled by various factors, including cytokines, lymphokines, and chemokines. Each of these molecules signals the B cells to differentiate into a certain type of plasma cell.